Research Analysts’ Weekly Ratings Updates for Centene (CNC)

A number of firms have modified their ratings and price targets on shares of Centene (NYSE: CNC) recently:

  • 2/7/2018 – Centene had its price target raised by analysts at Credit Suisse Group AG from $110.00 to $112.00. They now have a “neutral” rating on the stock.
  • 2/7/2018 – Centene had its price target raised by analysts at Cantor Fitzgerald from $115.00 to $125.00. They now have an “overweight” rating on the stock.
  • 2/7/2018 – Centene had its price target raised by analysts at Morgan Stanley from $118.00 to $126.00. They now have an “overweight” rating on the stock.
  • 2/7/2018 – Centene had its “outperform” rating reaffirmed by analysts at Citigroup Inc. They now have a $130.00 price target on the stock, up previously from $122.00.
  • 2/2/2018 – Centene was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 1/3/2018 – Centene is now covered by analysts at Goldman Sachs Group Inc. They set a “buy” rating and a $135.00 price target on the stock.
  • 12/31/2017 – Centene was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 12/26/2017 – Centene was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $117.00 price target on the stock. According to Zacks, “Year to date, Centene’s shares have outperformed the industry. The company’s strong and consistent performance is likely to have generated confidence among the investors. It has seen substantial inorganic growth in the last five years. The acquisition of Health Net in 2016 bolstered the company’s growth, expansion and asset base. Its solid financial position provides a major boost to its capital deployment initiatives. The company’s strong Managed care segment also contributes to its strong results. The guidance raise for 2017 and strong earnings outlook for 2018 instills shareholders' confidence in the company. However, rising level of debt hurts the company's profitability. Moreover, increasing costs also continue to weigh on the margins.”
  • 12/22/2017 – Centene was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Year to date, Centene’s shares have outperformed the industry. The company’s strong and consistent performance is likely to have generated confidence among the investors. It has seen substantial inorganic growth in the last five years. The acquisition of Health Net in 2016 bolstered the company’s growth, expansion and asset base. Its solid financial position provides a major boost to its capital deployment initiatives. The company’s strong Managed care segment also contributes to its strong results. The guidance raise for 2017 and strong earnings outlook for 2018 instills our confidence in the company. However, rising level of debt hurts the company's profitability. Moreover, increasing costs also continue to weigh on the margins.”
  • 12/20/2017 – Centene had its price target raised by analysts at Oppenheimer Holdings Inc. from $111.00 to $122.00. They now have an “outperform” rating on the stock.
  • 12/18/2017 – Centene had its price target raised by analysts at Jefferies Group LLC from $112.00 to $115.00. They now have a “buy” rating on the stock.
  • 12/18/2017 – Centene had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $134.00 price target on the stock.
  • 12/18/2017 – Centene had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $115.00 price target on the stock. They wrote, “Individual market outlook remains solid. CNC indicates that individual exchange membership (for 2018 coverage year) has been in line with its expectations. CNC is the only company in our managed care coverage universe to materially benefit from exchanges. We attribute the success to the strategy to target certain demographics in existing Medicaid markets. The company believes (and we agree) that the potential repeal of the mandate should not have an impact on membership as most of its members are highly subsidized.””
  • 12/15/2017 – Centene had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $111.00 price target on the stock.

Centene Corporation (CNC) opened at $101.66 on Monday. The company has a quick ratio of 0.99, a current ratio of 0.93 and a debt-to-equity ratio of 0.68. The firm has a market cap of $17,631.61, a P/E ratio of 21.68, a P/E/G ratio of 0.96 and a beta of 0.71. Centene Corporation has a twelve month low of $65.03 and a twelve month high of $112.42.

Centene (NYSE:CNC) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.03. The firm had revenue of $12.81 billion during the quarter, compared to analysts’ expectations of $12.25 billion. Centene had a net margin of 1.71% and a return on equity of 13.68%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.19 earnings per share. research analysts expect that Centene Corporation will post 7.23 EPS for the current fiscal year.

In other Centene news, Director Robert K. Ditmore sold 8,750 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $104.30, for a total transaction of $912,625.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jesse N. Hunter sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $98.73, for a total transaction of $987,300.00. The disclosure for this sale can be found here. Insiders sold 23,750 shares of company stock valued at $2,400,475 in the last 90 days. Company insiders own 3.00% of the company’s stock.

Centene Corporation is a healthcare company. The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. The Company operates through two segments: Managed Care and Specialty Services. The Company’s Managed Care segment provides health plan coverage to individuals, through government subsidized programs, including Medicaid, the State Children’s Health Insurance Program (CHIP), Long Term Care, Foster Care, dual-eligible individuals (Duals) and the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare, and Health Insurance Marketplace.

Receive News & Ratings for Centene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply